A new market study, titled “Orphan drugs for AML – Competitive Landscape and Market, Market Access Potential, Pricing & Pipeline Analysis, 2018”, has been featured on WiseGuyReports.
The research report ‘Orphan drugs for AML – Competitive Landscape and Market, Market Access Potential, Pricing & Pipeline Analysis, 2018′ provides the comprehensive list of orphan drugs that are indicated for acute myeloid leukemia. The main objective of this report is to provide a comprehensive secondary research and market analysis of orphan drugs that are indicated for treating acute myeloid leukemia. This report also includes the market access and reimbursement challenges across EU5 and US. With Vidaza indicated as standard of care and the low dose cytabine indicated as well (off label), there are opportunities and challenges involved in the new drug development. Understanding the market access challenges of the recently approved drugs, there are many key takeaways which are presented in the current report. This report also includes the pipeline products that are in Phase 3, Phase 2, Phase 1, & preclinical stage of development. This report also provides comprehensive research on the companies that are working on AML inhibitors including the deals and acquisitions.
The report is built with the in-depth secondary research, understanding the market access aspects across the different countries.
Noventia Pharma Srl
Janssen-Cilag International N V
Ariad Pharma Ltd
Novartis Europharm Ltd
Celgene Europe Limited
Request Sample Report at https://www.wiseguyreports.com/sample-request/3077000-orphan-drugs-for-aml-competitive-landscape-and-market
Table of Content
- Disease Landscape
- Key updates:
- Executive summary
- Market Outlook
- Orphan drug
- Epidemiology Overview
- Current treatment overview
- Companies working on AML drugs
- Emerging treatment overview
- Access and Reimbursement Overview
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)